Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nutrition Labeling Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Menu Label Noticeability

NCT06204913
View directory record Official record
Conditions
Noticing Nutrition Information, Recalling Nutrition Information
Interventions
Menu label
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
4,581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 2:15 PM EDT
Terminated Phase 3 Interventional

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

NCT07197034
View directory record Official record
Conditions
Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
Interventions
ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
13 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Not applicable Interventional

PACIFIC-FIT: Providing Adults Collaborative Interventions for Ideal Changes Focused Intervention and Tracking

NCT03914508
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Memory + Behavioral Weight Loss
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heat Wrap Device Safety With Age and Body Fat

NCT01355653
View directory record Official record
Conditions
Back Pain
Interventions
thermal therapy, ThermaCare heatwrap
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 17, 2026, 2:15 PM EDT
Withdrawn Phase 4 Interventional

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

NCT03481894
View directory record Official record
Conditions
Malnutrition
Interventions
Kabiven®, Compounded standard parenteral nutrition
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 17, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

LGCP (Laparoscopic Greater Curvature Plication)

NCT01393886
View directory record Official record
Conditions
Obesity
Interventions
Laparoscopic Greater Curvature Plication (LGCP)
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

NCT00991107
View directory record Official record
Conditions
Insulin Resistance
Interventions
HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 17, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 3 Interventional

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
mibavademab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Results available

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

NCT04621227
View directory record Official record
Conditions
Obesity
Interventions
PF-06882961, Rosuvastatin, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 17, 2026, 2:15 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942
View directory record Official record
Conditions
Psoriasis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
39
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Video Gaming to Evaluate Front of Pack Labeling With Children

NCT03482336
View directory record Official record
Conditions
Child Obesity
Interventions
Four FOP label designs
Other
Lead sponsor
Michigan State University
Other
Eligibility
6 Years to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 17, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

NCT07710768
View directory record Official record
Conditions
Obesity, Overweight
Interventions
UBT251, Cocktail (Warfarin/Caffeine/Midazolam)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

NCT05879614
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
NNZ-2591
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
4 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
San Diego, California • Atlanta, Georgia • Chevy Chase, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

NCT03961360
View directory record Official record
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Obesity
Interventions
Aspirin 81 mg, Aspirin 162 mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

NCT03198767
View directory record Official record
Conditions
Obesity
Interventions
LIK066, Carbohydrate 50%, Carbohydrate 25%, Carbohydrate 8%, Carbohydrate 0%, Psyllium, Calcium carbonate
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

NCT07717814
View directory record Official record
Conditions
Overweight and Obesity
Interventions
AMG 133 (frozen liquid), AMG 133 (liquid)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 17, 2026, 2:15 PM EDT
Active, not recruiting No phase listed Observational

An Open Label 100 Person Study Evaluating a Natural Supplement for Weight Loss and Fat Loss.

NCT07152470
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Diet and Exercise Tracking
Behavioral
Lead sponsor
Prostasis, LLC, dba Tonum Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Timeline
2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

NCT03714373
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo for DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Orange, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Climate Impact Label Design and Fast-Food Meal Selection

NCT06678178
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Warning High Climate Impact Labels, Traffic Light Labels, Climate Grade Labels, Numeric Carbon Footprint Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
6,622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013
View directory record Official record
Conditions
Obesity, Obese, Overweight or Obesity
Interventions
Bimagrumab, Semaglutide, Placebo
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 17, 2026, 2:15 PM EDT